MEDI-528, now recognized as enokizumumab, represents a novel treatment targeting the IGF1R, a key protein implicated in several skin conditions . Early trial data suggest considerable efficacy for the https://alvindelr197922.blog-gold.com/58252014/enokizumab-a-deep-dive-into-medi-528-and-its-potential